Kura Oncology Inc

KURA06 Dec 2024
Healthcare
$10.81
-0.02 (-2.10%)
Lowest Today
$10.55
Highest Today
$10.92
Today’s Open
$10.81
Prev. Close
$10.94
52 Week High
$24.17
52 Week Low
$9.68
To Invest in Kura Oncology Inc

Kura Oncology Inc

Healthcare
KURA06 Dec 2024
-0.02 (-2.10%)
1M
3M
6M
1Y
5Y
Low
$10.54
Day’s Range
High
$10.92
10.54
52 Week Low
$9.68
52-Week Range
52 Week High
$24.17
9.68
1 Day
-
1 Week
-2.81%
1 month return
-39.86%
3 month return
-44.45%
6 month return
-51.47%
1 Year return
-3.33%
3 Years return
-13.55%
5 Years return
-31.3%
10 Years return
-
Institutional Holdings
Suvretta Capital Management, LLC
9.84
BlackRock Inc
8.96
EcoR1 Capital, LLC
7.47
Deerfield Management Co
6.96
Paradigm Biocapital Advisors LP
5.57
Vanguard Group Inc
5.41
venBio Select Advisor LLC
4.55

Market Status

Fundamentals
Market Cap
850.74 mln
PB Ratio
2.05
PE Ratio
0
Enterprise Value
412.07 mln
Total Assets
448.94 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Organisation
Kura Oncology Inc
Employees
142
Industry
Biotechnology
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities